Ticagrelor reduces thrombus formation more than clopidogrel, even when co-administered with bivalirudin

M. Urooj Zafar; David A. Vorchheimer; Mita Patel Tewar; Chiara Giannarelli; Matteo Crippa; Samantha Sartori; David Rodriguez; Usman Baber; Roxana Mehran; Juan J. Badimon

doi:10.1160/th14-03-0269

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2014; 112(05): 1069-1070
DOI: 10.1160/th14-03-0269

Letters to the Editor

Schattauer GmbH

Ticagrelor reduces thrombus formation more than clopidogrel, even when co-administered with bivalirudin

M. Urooj Zafar

¹Cardiovascular Institute, Icahn School of Medicine at Mount Sinai New York, New York, USA

,

David A. Vorchheimer

¹Cardiovascular Institute, Icahn School of Medicine at Mount Sinai New York, New York, USA

,

Mita Patel Tewar

¹Cardiovascular Institute, Icahn School of Medicine at Mount Sinai New York, New York, USA

,

Chiara Giannarelli

¹Cardiovascular Institute, Icahn School of Medicine at Mount Sinai New York, New York, USA

,

Matteo Crippa

¹Cardiovascular Institute, Icahn School of Medicine at Mount Sinai New York, New York, USA

,

Samantha Sartori

¹Cardiovascular Institute, Icahn School of Medicine at Mount Sinai New York, New York, USA

,

David Rodriguez

¹Cardiovascular Institute, Icahn School of Medicine at Mount Sinai New York, New York, USA

,

Usman Baber

¹Cardiovascular Institute, Icahn School of Medicine at Mount Sinai New York, New York, USA

,

Roxana Mehran

¹Cardiovascular Institute, Icahn School of Medicine at Mount Sinai New York, New York, USA

,

Juan J. Badimon

¹Cardiovascular Institute, Icahn School of Medicine at Mount Sinai New York, New York, USA

› Author Affiliations

Abstract

Full Text

References

References
1 Stone GW, Witzenbichler B, Guagliumi G. et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358: 2218-2230.
2 Gurbel PA, Bliden KP, Samara W. et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46: 1827-1832.
3 Dangas G, Mehran R, Guagliumi G. et al. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol 2009; 54: 1438-1446.
4 Gurbel PA, Bliden KP, Butler K. et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120: 2577-2585.
5 Kirkby NS, Leadbeater PD, Chan MV. et al. Anti-platelet effects of aspirin vary with level of P2Y(1)(2) receptor blockade supplied by either ticagrelor or prasugrel. J Thromb Haemost 2011; 9: 2103-2105.
6 Shimbo D, Osende J, Chen J. et al. Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin. Thromb Haemost 2002; 88: 733-738.
7 Lev EI, Patel R, Karim A. et al. Anti-thrombotic effect of bivalirudin compared with eptifibatide and unfractionated heparin in diabetic patients: an ex vivo human study. Thromb Haemost 2006; 95: 441-446.
8 Zafar MU, Ibanez B, Choi BG. et al. A new oral antiplatelet agent with potent antithrombotic properties: comparison of DZ-697b with clopidogrel a randomised phase I study. Thromb Haemost 2010; 103: 205-212.